These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32168749)

  • 1. Evaluation of Glycosylated PTGS2 in Colorectal Cancer for NSAIDS-Based Adjuvant Therapy.
    Venè R; Costa D; Augugliaro R; Carlone S; Scabini S; Casoni Pattacini G; Boggio M; Zupo S; Grillo F; Mastracci L; Pitto F; Minghelli S; Ferrari N; Tosetti F; Romairone E; Mingari MC; Poggi A; Benelli R
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy.
    Benelli R; Venè R; Ferrari N
    Transl Res; 2018 Jun; 196():42-61. PubMed ID: 29421522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer: An update.
    Jaén RI; Prieto P; Casado M; Martín-Sanz P; Boscá L
    World J Gastroenterol; 2018 Dec; 24(48):5454-5461. PubMed ID: 30622375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer.
    Mehta RS; Song M; Bezawada N; Wu K; Garcia-Albeniz X; Morikawa T; Fuchs CS; Ogino S; Giovannucci EL; Chan AT
    J Natl Cancer Inst; 2014 Apr; 106(4):dju016. PubMed ID: 24565956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
    Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
    Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases.
    Goos JA; Hiemstra AC; Coupé VM; Diosdado B; Kooijman W; Delis-Van Diemen PM; Karga C; Beliën JA; Menke-van der Houven van Oordt CW; Geldof AA; Meijer GA; Hoekstra OS; Fijneman RJ; ;
    Br J Cancer; 2014 Aug; 111(4):749-55. PubMed ID: 24983372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality.
    Mehta RS; Chong DQ; Song M; Meyerhardt JA; Ng K; Nishihara R; Qian Z; Morikawa T; Wu K; Giovannucci EL; Fuchs CS; Ogino S; Chan AT
    Gastroenterology; 2015 Sep; 149(3):614-22. PubMed ID: 26026393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    Hamy AS; Tury S; Wang X; Gao J; Pierga JY; Giacchetti S; Brain E; Pistilli B; Marty M; Espié M; Benchimol G; Laas E; Laé M; Asselain B; Aouchiche B; Edelman M; Reyal F
    J Clin Oncol; 2019 Mar; 37(8):624-635. PubMed ID: 30702971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-2 inhibition as a tool to treat and prevent colorectal cancer.
    Tuynman JB; Peppelenbosch MP; Richel DJ
    Crit Rev Oncol Hematol; 2004 Nov; 52(2):81-101. PubMed ID: 15501074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.
    Ulrich CM; Whitton J; Yu JH; Sibert J; Sparks R; Potter JD; Bigler J
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):616-9. PubMed ID: 15767339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.
    Chen WS; Wei SJ; Liu JM; Hsiao M; Kou-Lin J; Yang WK
    Int J Cancer; 2001 Mar; 91(6):894-9. PubMed ID: 11275997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.
    Mima K; Nishihara R; Yang J; Dou R; Masugi Y; Shi Y; da Silva A; Cao Y; Song M; Nowak J; Gu M; Li W; Morikawa T; Zhang X; Wu K; Baba H; Giovannucci EL; Meyerhardt JA; Chan AT; Fuchs CS; Qian ZR; Ogino S
    Clin Cancer Res; 2016 Aug; 22(15):3841-8. PubMed ID: 26957558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer.
    Moon CM; Kwon JH; Kim JS; Oh SH; Jin Lee K; Park JJ; Pil Hong S; Cheon JH; Kim TI; Kim WH
    Int J Cancer; 2014 Feb; 134(3):519-29. PubMed ID: 23852449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.
    Reimers MS; Bastiaannet E; Langley RE; van Eijk R; van Vlierberghe RL; Lemmens VE; van Herk-Sukel MP; van Wezel T; Fodde R; Kuppen PJ; Morreau H; van de Velde CJ; Liefers GJ
    JAMA Intern Med; 2014 May; 174(5):732-9. PubMed ID: 24687028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.
    Makar KW; Poole EM; Resler AJ; Seufert B; Curtin K; Kleinstein SE; Duggan D; Kulmacz RJ; Hsu L; Whitton J; Carlson CS; Rimorin CF; Caan BJ; Baron JA; Potter JD; Slattery ML; Ulrich CM
    Cancer Causes Control; 2013 Dec; 24(12):2059-75. PubMed ID: 24022467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.
    Lu Y; Shi C; Qiu S; Fan Z
    Oncotarget; 2016 Oct; 7(40):64766-64777. PubMed ID: 27074568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of COX-2 in intestinal inflammation and colorectal cancer.
    Wang D; Dubois RN
    Oncogene; 2010 Feb; 29(6):781-8. PubMed ID: 19946329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer.
    Maihöfner C; Charalambous MP; Bhambra U; Lightfoot T; Geisslinger G; Gooderham NJ;
    Carcinogenesis; 2003 Apr; 24(4):665-71. PubMed ID: 12727794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL1β-mediated Stromal COX-2 signaling mediates proliferation and invasiveness of colonic epithelial cancer cells.
    Zhu Y; Zhu M; Lance P
    Exp Cell Res; 2012 Nov; 318(19):2520-30. PubMed ID: 22884582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
    Richter M; Weiss M; Weinberger I; Fürstenberger G; Marian B
    Carcinogenesis; 2001 Jan; 22(1):17-25. PubMed ID: 11159736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.